This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics.
SUNDAY, Feb. 16, 2025 -- Flu season is in full swing, making it more important than ever to take steps to protect yourself and your loved ones.Dr. Priya Soni, a pediatric infectious disease specialist at Cedars-Sinai Guerin Childrens Health Center.
The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, pharmaceutical companies are looking for innovative ways to stay ahead of the competition. One strategy that's gaining traction is biosimilar-to-biosimilar switching. But what does this mean, and how can you make it work for your business? Biosimilar-to-biosimilar switching involves switching patients from one biosimilar to another, often to improve efficacy, reduce costs, or enhance patient o
This article is best experienced on our website. In the late 1990s, a young physicist named Michael Elowitz decided to “program” living cells. A graduate student at Princeton University, Elowitz was spending a great deal of his free time poring over esoteric papers about circadian clocks, the molecular networks that control an organism’s behavior in roughly 24-hour cycles. “And as I’m reading all of these papers,” he told Asimov Press , “I noticed that m
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content